Merck & Co., Inc. to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company’s investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26.